Ticket purchases for Cheyenne Frontier Nights are temporarily on hold due to an issue with the event ticketing partner's ...

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Investment analysts at Zacks Research cut their Q1 2025 earnings per share estimates for shares of AXIS Capital in a research ...

Cheyenne Frontier Days has postponed ticket sales to Monday after its ticketing partner AXS reported a bot attack.

KBW analyst Meyer Shields maintained a Buy rating on Axis Capital (AXS – Research Report) today and set a price target of $118.00. The ...

Keefe Bruyette analyst Meyer Shields raised the firm’s price target on Axis Capital (AXS) to $118 from $115 and keeps an Outperform rating on ...

A rush among users to withdraw funds forced the firm to temporarily suspend instant withdrawals, but founder and CEO Walter ...

Chocolate Finance paused instant withdrawals due to a surge in AXS bill payments, driven by users maximising its miles reward ...

CFD says ''The AXS team is actively reinforcing measures to protect against automated purchases and ensure a fair buying ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...